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ABSTRACT
Introduction: Numerous real-world studies have compared non-vitamin K antagonist oral antic-
oagulants (NOACs) with vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrilla-
tion (NVAF). A meta-analysis was performed to synthesize the available evidence.
Methods: Systematic searches were performed through 12/2016 to identify non-randomized
NVAF studies comparing NOACs with VKAs, and reporting effectiveness, safety, or persistence.
Results: Of 562 citations identified, 49, 79, and 18 compared rivaroxaban, dabigatran, and
apixaban, respectively, with VKAs and were included. Compared with VKAs, rivaroxaban was
associated with a reduced risk of ischemic stroke (IS) (hazard ratio [HR] = 0.83, 95% confidence
interval [CI] = 0.75–0.93), intracranial haemorrhage (ICH) (HR = 0.69, 95% CI = 0.52–0.90), and non-
persistence (HR = 0.62, 95% CI = 0.60–0.65). Dabigatran was associated with a significantly lower
risk of IS (HR = 0.80, 95% CI = 0.65–0.98) and ICH (HR = 0.45, 95% CI = 0.36–0.58), but not for non-
persistence (HR = 0.91, 95% CI = 0.53–1.55), compared with VKAs. Apixaban was associated with
a lower risk of ICH than VKAs (HR = 0.41, 95% CI = 0.28–0.60), but was not different to VKAs in
terms of IS (HR = 1.01, 95% CI = 0.87–1.17) or non-persistence (HR = 1.08, 95% CI = 0.81–1.45).
Conclusion: NOACs appear to be at least as effective and safe as VKAs for stroke prevention in
patients with NVAF.
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Non-valvular atrial fibrillation (NVAF) refers to atrial fibril-
lation (AF) not accompanied by rheumatic mitral valve
disease, prosthetic heart valve, or valve repair [1]. NVAF is
themost common type of AF in the developed countries,
with major etiological factors including hypertension,
atherosclerotic heart disease, congestive heart failure,
and diabetes mellitus [2]. Although AF is often asympto-
matic, patients may present with symptoms that impair
their quality of life, such as discomfort, palpitations,
breathlessness, syncope, dizziness, reduced exercise tol-
erance, and chronic fatigue [3]. AF can have serious
cardiovascular consequences – it is associated with an
approximately two- to sevenfold increase in the risk of
stroke and a twofold increase in the risk of death [1]. The
risk of stroke increases with age, and as many as 1 in 6
ischemic strokes (ISs) occur in patients with AF [1]. The
prevalence of AF is 0.4–1% globally, and up to 10% in
those aged over 80 years [3]; it is expected to rise in the
coming years [2].
Anticoagulation in patients with AF aims to prevent IS.
Vitamin K antagonists (VKAs) were the first anticoagulants
used in patients with AF [4], and for a long time remained
the mainstay of therapy. Treatment with VKAs reduces the
risk of stroke by two-thirds andmortality by one-quarter [4].
However, VKAs require regular coagulation monitoring,
with dosage adjustments as required [4], and are associated
with numerous drug and food interactions [5]. Non-vitamin
K antagonist oral anticoagulants (NOACs) do not require
regular coagulationmonitoring [4], and their clinical benefit
in patients with NVAF is well established, following the
results of randomized controlled trials (RCTs) (ROCKET AF
[6], RE-LY [7] ARISTOTLE [8], and ENGAGE AF-TIMI 48 [9]), in
which they demonstrated similar or better efficacy com-
pared with VKAs [6–9], accompanied by a reduction in
haemorrhagic strokes (HSs) [7–9] and intracranial haemor-
rhage (ICH) [6–9]. Consequently, recent European Society of
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Cardiology (ESC) guidelines have recommended NOACs to
be initiated in preference to VKAs in eligible patients with
NVAF [4].
In addition to a substantial body of evidence from
RCTs, the emerging real-world evidence (RWE) on
NOACs represents an opportunity to demonstrate
their impact on everyday clinical practice. VKAs are
known to be drugs that perform well in RCTs.
However, due to the requirement for regular coagula-
tion monitoring and the potential for drug–food inter-
actions, VKAs are thought to be less efficient in real-
world settings. Moreover RWE provides information on
outcomes that may not be considered in RCTs, such as
persistence. This paper aims to synthesize the large
quantity of RWE available to evaluate the performance
of the NOACs (rivaroxaban, dabigatran, and apixaban)
compared with VKAs in patients with NVAF, by con-
ducting a meta-analysis of the available evidence.
Methods
A systematic review of RWE studies enrolling patients
with NVAF was the basis for this meta-analysis. The
methodology of the review adhered to the guidance
from the Centre for Reviews and Dissemination (CRD)
from the University of York [10] and the Cochrane
Handbook for Systematic Reviews of Interventions
[11]. Detailed results of the SLR were published sepa-
rately [12].
The population of interest was adults (aged
≥18 years) with NVAF receiving an oral anticoagulant.
Both studies reporting on incident (i.e., beginning antic-
oagulant treatment) and prevalent (i.e., continuing treat-
ment) patients were included. The interventions of
interest were the Factor Xa inhibitors apixaban and riv-
aroxaban and the direct thrombin inhibitor dabigatran.
The following databases were searched on 1
December 2016: Medline and Embase (accessed using
the Ovid platform), and the Cochrane Library (accessed
via Wiley Interscience), including the Cochrane Database
of Systematic Reviews (CDSR), Database of Abstracts of
Reviews of Effects (DARE), the Cochrane Central Register
of Controlled Trials (CENTRAL), the Health Technology
Assessment (HTA) database, and the NHS Economic
Evaluation Database (NHS EED). No restrictions were
applied in terms of publication date, language, or geogra-
phical scope. Details of the search strategy are presented in
the Supplementary Material.
Two independent reviewers performed the study
selection, and any differences were resolved by a third
reviewer. Extracted data were those on citation charac-
teristics, study details, patient characteristics, results,
and study limitations; all extracted data were quality-
checked by a second reviewer.
The outcomes of interest relating to drug efficacy were:
IS, all-cause mortality, myocardial infarction (MI), venous
thromboembolism (VTE), a composite of ischemic stroke
or systemic embolism (IS/SE), and a composite of IS/SE/all-
cause mortality. Outcomes of interest relating to drug
safety were: HS, ICH, major bleeding, gastrointestinal (GI)
bleeding, and any bleeding. A final outcome of interest
was persistence/non-persistence, defined as a break in
treatment of at least 60 days.
The following three comparisons were made: 1) rivar-
oxaban vs. VKAs, 2) dabigatran vs. VKAs, and 3) apixaban
vs. VKAs using the inverse variance-weighted method to
pool hazard ratios (HRs) and their 95% confidence inter-
vals (CIs) in a meta-analysis. The inverse variance-
weightedmethod was used based on a common assump-
tion that the ln(HR) followed a normal distribution. The
analysis was conducted on HRs to take into account
adjustments on baseline characteristics made in each
study. In line with previously published methodology
[13], when no HR was available the incidence rate ratio
was used instead. If there were no events in one arm of
a study, a continuity correction was applied, while studies
with no events in either treatment arm were excluded
from the analyses [11]. Details of input calculations are
provided in the Supplementary Material.
If results at different follow-up times were available in
a study, the longest follow-up was used. Additionally, if
more than one study used the same database, only the
study with the highest level of precision was used (i.e.,
only the study for which the standard error of the log of
HR was the smallest was included). For example, 21
studies assessing dabigatran vs. VKAs based on the
MarketScan® database were identified. Inclusion of stu-
dies using the same database and investigating similar
outcomes could lead to the same patients being repeat-
edly included in the analysis, which could bias the
results. Analyses did not account for different doses
(i.e., data for 15 mg and 20 mg rivaroxaban doses, and
110 mg and 150 mg dabigatran doses were pooled
together).
Heterogeneity between studies was assessed using the
p-value of the Cochrane Q test and the I-squared, as
recommended by the Cochrane Handbook for Systematic
Reviews of Interventions [11]. Both the fixed- and random-
effects models were fitted. Given the heterogeneity
between study designs, results of the random-effects
model are presented. Analyses were conducted using SAS
9.3®. Meta-analysis results are presented in the text as the
number of studies included in the comparison (n), and HR
with its [95% CI], unless otherwise indicated.
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Results
From 562 citations identified through the literature search,
95 were included in the meta-analysis following detailed
assessment [12]. Of these, 49 compared rivaroxaban with
VKA, 79 dabigatran with VKA, and 18 apixaban with VKAs
(some studies concerned more than one NOAC). The num-
ber of studies presenting results for each outcome of inter-
est varied, and is indicated for each comparison in the
forest plots (Figures 1–3).
Results of the meta-analysis comparing rivaroxaban
with VKAs are presented in Figure 1. Based on the
pooled outcomes of eight studies, rivaroxaban was asso-
ciated with significantly lower risk of IS (n = 8, HR [95%
CI]: 0.83 [0.75–0.93]). However, the use of rivaroxaban
yielded no significant difference between the treatments
for the risk of MI (n = 5) and VTE (n = 2). In the pooled
results of five studies, rivaroxaban was associated with
significantly lower all-cause mortality risk than VKAs (HR
[95% CI]: 0.50 [0.29–0.85]). A significantly lower risk with
rivaroxaban compared with VKAs was also observed for
two composite endpoints: IS/SE (n = 6, HR [95% CI]: 0.79
[0.70–0.88]) and IS/SE/mortality (n = 3, HR [95% CI]: 0.91
[0.84–0.98]). Further, the use of rivaroxaban resulted in
a lower risk of ICH (n = 10, HR [95% CI]: 0.69 [0.52, 0.90]).
For HS (n = 2) there was no significant difference found
between rivaroxaban and VKAs. In terms of notable
differences in safety, VKAs were associated with a lower
risk of GI bleeding than rivaroxaban (n = 8, HR [95% CI]:
1.22 [1.12–1.33]). No significant differences between the
two treatments were observed in the risk of major bleed-
ing (n = 21) and any bleeding (n = 6). Finally, lack of
persistence with treatment was less of a risk with rivar-
oxaban than VKAs (n = 3, HR [95% CI]: 0.62 [0.60–0.65]).
When an analogous comparison was performed
between dabigatran and VKAs (Figure 2), the NOAC
was associated with a lower risk of IS (n = 10, HR [95%
CI]: 0.80 [0.65–0.98]). No significant difference was
found between the two treatments in the risk of MI
(n = 11). The NOAC was also associated with a lower
risk for VTE (n = 4, HR [95% CI]: 0.72 [0.64–0.81]) and
all-cause mortality (n = 15, HR [95% CI]: 0.65
[0.55–0.76]). No significant difference was detected
between the two treatments for two composite end-
points, IS/SE (n = 3) and IS/SE/mortality (n = 1).
Dabigatran was associated with a lower risk for ICH
(n = 14, HR [95% CI]: 0.45 [0.36–0.58]) and HS (n = 4,
HR [95% CI]: 0.50 [0.41–0.62]). Pooled results of 18
studies suggested GI bleeding was significantly less
of a risk in patients treated with VKAs than in those
receiving dabigatran (HR [95% CI]: 1.12 [1.02–1.24]).
Dabigatran was also associated with a lower risk in
major bleeding (n = 24, HR [95% CI]: 0.80 [0.71–0.91])
and any bleeding (n = 9, HR [95% CI]: 0.67 [0.48–0.93]).




HR [95% CI] HR [95% CI]
Ischaemic stroke (N=8) 243,165 0.83 [0.75 ; 0.93]
Myocardial infarction (N=5) 175,213 0.96 [0.80 ; 1.14]
Venous Thromboembolism (N=2) 31,720 0.78 [0.26 ; 2.37]
All-cause of mortality (N=5) 59,077 0.50 [0.29 ; 0.85]
Composite of IS/SE (N=6) 139,819 0.79 [0.70 ; 0.88]
Composite of IS/SE/mortality (N=3) 80,944 0.91 [0.84 ; 0.98]
Intracranial haemorrhage (N=10) 317,787 0.69 [0.52 ; 0.90]
Haemorrhage stroke (N=2) 50,620 0.64 [0.37 ; 1.10]
Gastrointestinal bleeding (N=8) 224,834 1.22 [1.12 ; 1.33]
Major bleeding (N=21) 422,244 1.05 [0.93 ; 1.18]
Any bleeding (N=6) 111,112 0.96 [0.89 ; 1.05]
Non-persistence (N=3) 43,437 0.62 [0.60 ; 0.65]
0.10 1.00 10.00Favours VKA
Figure 1. Meta-analysis results for rivaroxaban versus VKA.
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No significant difference between the two therapies
detected in terms of the risk of non-persistence (n = 3).
Finally, apixaban was compared with VKAs (Figure 3).
Meta-analyses showed that were no significant
differences detected between apixaban and VKAs for
IS (n = 4), all-cause mortality (n = 2) and for the com-
posite endpoint of IS/SE (n = 1). Apixaban was asso-





HR [95% CI] HR [95% CI]
Ischaemic stroke (N=4) 65,755 1.01 [0.87 ; 1.17]
Myocardial infarction (N=0) - -
Venous Thromboembolism (N=0) - -
All-cause of mortality (N=2) 45,933 0.32 [0.05 ; 2.08]
Composite of IS/SE (N=1) 41,785 1.01 [0.86 ; 1.18]
Composite of IS/SE/mortality (N=1) 41,785 0.78 [0.71 ; 0.86]
Intracranial haemorrhage (N=4) 48,963 0.41 [0.28 ; 0.60]
Haemorrhage stroke (N=1) 15,390 0.35 [0.14 ; 0.88]
Gastrointestinal bleeding (N=3) 19,952 0.52 [0.38 ; 0.70]
Major bleeding (N=7) 109,636 0.69 [0.63 ; 0.75]
Any bleeding (N=3) 72,843 0.88 [0.54 ; 1.42]
Non-persistence (N=1) 9,959 1.08 [0.81 ; 1.45]
Favours VKA0.10 1.00 10.00





HR [95% CI] HR [95% CI]
Ischaemic stroke (N=10) 219,508 0.80 [0.65 ; 0.98]
Myocardial infarction (N=11) 400,474 0.85 [0.72 ; 1.00]
Venous Thromboembolism (N=4) 130,129 0.72 [0.64 ; 0.81]
All-cause of mortality (N=15) 348,597 0.65 [0.55 ; 0.76]
Composite of IS/SE (N=3) 87,465 0.89 [0.67 ; 1.19]
Composite of IS/SE/mortality (N=1) 28,156 0.96 [0.79 ; 1.17]
Intracranial haemorrhage (N=14) 509,995 0.45 [0.36 ; 0.58]
Haemorrhage stroke (N=4) 119,379 0.50 [0.41 ; 0.62]
Gastrointestinal bleeding (N=18) 417,735 1.12 [1.02 ; 1.24]
Major bleeding (N=24) 501,900 0.80 [0.71 ; 0.91]
Any bleeding (N=9) 286,924 0.67 [0.48 ; 0.93]
Non-persistence (N=3) 11,054 0.91 [0.53 ; 1.55]
Favours VKA0.10 1.00 10.00
Figure 2. Meta-analysis results for dabigatran versus VKA.
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endpoint of IS/SE/mortality (HR [95% CI]: 0.78
[0.71–0.86]), ICH (n = 4, HR [95% CI]: 0.41 [0.28–0.60]),
HS (HR [95% CI]: 0.35 [0.14–0.88]), major bleeding
(n = 7, HR [95% CI]: 0.69 [0.63–0.75]) and GI bleeding
(n = 3, HR [95% CI]: 0.52 [0.38–0.70]). However, the
outcomes of IS/SE, IS/SE/mortality and HS, were only
reported in a single study each, therefore, a meta-
analysis was not conducted. Regarding other outcomes
of interest, no significant differences between apixaban
and VKAs were detected in terms of the risk of any
bleeding (n = 3), and non-persistence (n = 1). No stu-
dies comparing MI or VTE risk between apixaban and
VKAs were identified. The fact that less evidence is
available for apixaban (only 18 studies comparing apix-
aban with VKAs were included in the present meta-
analysis) probably explains why there are not as many
significant results for apixaban in comparison to rivar-
oxaban and dabigatran.
Discussion
The SLR identified a large number of studies, highlight-
ing a substantial interest in RWE on NOACs in NVAF.
Given the large volume of evidence, a meta-analysis of
the data allows us to obtain a clearer picture on the
performance of NOACs in comparison with the pre-
vious, long-standing standard of care – VKAs – in the
routine setting of clinical practice.
The results of the meta-analyses presented in this study
were broadly similar to those of the pivotal RCTs of rivar-
oxaban [6], dabigatran [7], and apixaban [8]. This meta-
analysis shows that patients treated with rivaroxaban
appeared at lower risk of IS or death from any cause than
those treated with VKAs, while the ROCKET AF study
detected no significant difference [6]. On the other hand,
ROCKET AF reported a significantly lower rate of HS in
patients treated with rivaroxaban. It is, however, worth
noting that the meta-analysis results on HS are based on
only two studies. The RE-LY study tested two doses of
dabigatran (110 and 150 mg) against warfarin [7], while
ourmeta-analysis pooled results for both dabigatran doses,
somewhat complicating comparison of the results. In the
ARISTOTLE trial, apixaban was superior to warfarin in terms
of the primary endpoint of the study – prevention of stroke
or SE [8]. However, in a meta-analysis of two RWE studies,
no significant difference was detected. Similarly, all-cause
mortality, which was significantly lower in the apixaban
arm than in the VKAs arm [8], did not differ significantly
between treatments in a meta-analysis of two real-world
studies.
It is widely recognized that real-world studies provide
information on the effectiveness of intervention in much
more diverse populations than those included in RCTs [14].
Furthermore, trial results are usually reported based on
intention-to-treat analysis, whereas RWE results are usually
based on on-treatment analysis. With intensivemonitoring,
good results were obtained with VKAs in clinical trials [6–8]
and one may expect the benefits of NOACs – which do not
require routinemonitoring – to bemore evident in the real-
world setting, where patients are usually not monitored as
closely as they are in clinical trials [15]. Themajor strengthof
the present analysis was the inclusion of numerous studies,
although a fewoutcomes analysedwere only based on one
single study. Furthermore, a large number of outcomes
were analysed, providing, overall, a substantially broader
range of information than a recently published meta-
analysis on a similar topic [16]. However, several methodo-
logical factors that could influence the results of this
meta-analysis are worth considering.
The populations of the studies included were some-
what heterogeneous, which is important considering
that the pivotal studies identified several patient and
disease characteristics that affected the safety and effi-
cacy of the NOACs analysed. In the pivotal study of
rivaroxaban, no interactions were observed between
these characteristics and the overall efficacy of the
drug in the intention-to-treat population. However, sev-
eral interactions were reported on the safety side in
ROCKET AF [6] and ARISTOTLE [8]. To account for poten-
tial confounding of baseline characteristics, the majority
of studies performed adjustments. Most of the studies
reported adjusted Cox HRs, with propensity score
matching, incidence rate ratio, and crude Kaplan–
Meier HR also being used. Although few of the citations
analysed reported unadjusted HRs, a recent publication
suggested that adjustment methods may substantially
influence study results [17]. Work on a complementary
analysis investigating the effect that different adjust-
ment methods may have on the robustness of meta-
analysis results is currently ongoing.
Considering the interventions (and comparators) used
in the included studies, many studies did not report the
NOAC dose used, which is a substantial limitation
because – with the exception of dabigatran – different
doses are indicated for different patient populations. In
addition, some studies mixed incident and prevalent
patients. This could pose an issue when evaluating bleed-
ing, which usually occurs in the initial phases of antic-
oagulant treatment [18], and so could be less common in
prevalent than incident patients.
Outcome definitions varied dramatically across stu-
dies, especially for major bleeding, which sometimes
pooled ICH and GI bleeding, despite NOACs showing
evidence for a reduced risk of ICH and increased risk of
GI bleeding [19]. Persistence was also defined differently
and only studies defining non-persistence as a refill gap
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of at least 60 days were included. Information on mortal-
ity, any bleeding and HS was not always collected, mak-
ing assessment of this outcome challenging. Therefore,
for the purpose of future analyses, ICH may be a more
relevant outcome than HS. Information on the severity
(major vs. minor) of GI bleeding was not provided.
Additionally, some studies presented results at different
follow-up times, in which case the longest available fol-
low-up was used in the analysis.
Despite the methodological issues we have mentioned,
an inclusive approach was used to capture the available
RWE on NOACs. Consequently, studies were not selected
based on the methods used to adjust HRs comparing
NOACs with VKAs, International Classification of Diseases
codes considered to derive outcomes of interest, or enrol-
ment of patients following cardioversion or ablation proce-
dures that may increase the risk of bleeding. Furthermore,
both abstracts and full-text citations were analyzed. Our
selection procedure aimed to avoid double-counting in
studies using the same database – a major methodological
issue associated withmeta-analyses of RWE [16]. A detailed
investigation of the effects that various methodological
differences between the studies included in a meta-
analysis may have on the results is currently in preparation.
Real-world studies are usually far more heterogeneous
than RCTs, with substantial differences between studies in
designs, populations, definitions of outcomes, and other
features, making a high-quality meta-analysis challenging.
It is worth noting that there is little guidance available to
researchers undertaking meta-analyses of real-world stu-
dies, with well-respected sources such as the CRD
Guidance for Undertaking Reviews in Healthcare [10],
the Cochrane Handbook for Systematic Reviews of
Interventions [11], among others, providing only limited
methodological support. Because the importance of RWE
is ever-growing, the development of guidelines for
pooled analysis could help prescribers, patients, and
payers alike to draw better-grounded conclusions on the
real-world effectiveness of healthcare interventions.
Ongoing research of RWE continues to support the
use of NOACs in routine daily practice, confirming RCT
findings. Real-world studies are usually far more het-
erogeneous than RCTs, with substantial differences
between studies in designs, populations, definitions
of outcomes, and other features. Whilst this can
prove challenging when performing a meta-analysis,
it is helpful to analyse safety and efficacy outcomes
across a broad range of patients with a long follow-up
time, which cannot be captured in RCTs. The availabil-
ity of RWE will increase over the next few years,
increasing physicians’ knowledge of how NOACs are
used in daily practice and supporting the optimization
of treatment in individual patients. In addition, the
development of guidelines for the pooled analysis of
RWE could help prescribers, patients, and payers alike,
to draw better-grounded conclusions on real-world
effectiveness of healthcare interventions.
Conclusion
Through an SLR, numerous studies comparing real-
world effectiveness of NOACs versus VKAs were identi-
fied. However, their methodology was rather heteroge-
neous, leading to some conflicting results. Synthesizing
these results in a meta-analysis demonstrated that
NOACs are a suitable alternative to VKAs in routine
clinical practice. In light of the scarce guidance for
conducting meta-analyses of real-world studies, addi-
tional sensitivity analyses may improve understanding
of the effect that differences in the methodologies
employed by the studies included in a meta-analysis
may have on the results.
Key issues
● Numerous real-world studies comparing NOACs
with VKAs in patients with NVAF have been pub-
lished. A meta-analysis was performed to synthe-
size the available evidence.
● Rivaroxaban and dabigatran, but not apixaban,
were associated with significant reduced risks of IS
compared to VKA. Rivaroxaban was also associated
with a reduced risk of non-persistence versus VKAs.
In this meta-analysis, all NOACs were associated
with a lower incidence of ICH compared to VKAs.
● NOACs appear to be at least as effective and safe
as VKAs for stroke prevention in NVAF.
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